CDKN2A and cancer: The Cancer 10-Pathway Reporter Assay revealed that upregulation of the p53 axis was associated with concomitant increases in the expression of downstream effectors, including p21, Myc/Max, and ARF, indicating coordinated activation of p53-dependent tumor-suppressive pathways.